Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT: A phase-2 trial
P Gimsing, Ø Hjertner, N Abildgaard, N F Andersen, T G Dahl, H Gregersen, T W Klausen, U-H Mellqvist, O Linder, R Lindås, N Tøffner Clausen, S Lenhoff
Dive into the research topics of 'Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT: A phase-2 trial'. Together they form a unique fingerprint.